Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.

doi:10.1038/s41375-020-0723-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.

Leukemia - 1 Jul 2020

Blakemore Stuart J, Clifford Ruth, Parker Helen, Antoniou Pavlos, Stec-Dziedzic Ewa, Larrayoz Marta, Davis Zadie, Kadalyayil Latha, Colins Andrew, Robbe Pauline, Vavoulis Dimitris, Forster Jade, Carr Louise, Morilla Ricardo, Else Monica, Bryant Dean, McCarthy Helen, Walewska Renata J, Steele Andrew J, Chan Jacqueline, Speight Graham, Stankovic Tanja, Cragg Mark S, Catovsky Daniel, Oscier David G, Rose-Zerilli Matthew J J, Schuh Anna, Strefford Jonathan C

Abstract excerpt

Despite advances in chronic lymphocytic leukaemia (CLL) treatment, globally chemotherapy remains a central treatment modality, with chemotherapy trials representing an invaluable resource to explore disease-related/genetic features contributing to long-term outcomes. In 499 LRF CLL4 cases, a trial with >12 years follow-up, we employed targeted resequencing of 22 genes, identifying 623 mutations. After background...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ataxia Telangiectasia Mutated Proteins

Share to Cyclophosphamide

Share to Extracellular Signal-Regulated MAP Kinases

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to MAP Kinase Signaling System

Share to Survival Rate

Share to Vidarabine

Source

Open in PubMed Open full text

Identifiers

PMID: 32015491
DOI: 10.1038/s41375-020-0723-2
PMCID: PMC7326706

Genes

TP53
ATM
KRAS
NFKBIE
SF3B1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.PMID 32015491Read ↗

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatmentSemantic proximity Read ↗

Molecular genetics of high-risk chronic lymphocytic leukemia.Semantic proximity Read ↗

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.Semantic proximity Read ↗

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.Semantic proximity Read ↗

Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.Semantic proximity Read ↗

The clinical implications of gene mutations in chronic lymphocytic leukaemia.Semantic proximity Read ↗

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.Semantic proximity Read ↗

The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia.Semantic proximity Read ↗

Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.Semantic proximity Read ↗

Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia.Semantic proximity Read ↗

High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.